Week One

25 - 29 October 2021

Market Insights & Product Innovation - Pharma Ingredients 

25th October 2021

On-Demand Webinar	Keynote: European Regulatory Outlook The Pharmaceutical Industry as a Key Asset to the EU Economy Pharmaceutical Strategy for Europe Supporting a Competitive & Innovative EU Pharmaceutical Industry Flagship Initiatives on Manufacturing Competitiveness and Regulatory Efficiency Driving Sustainable Post-Pandemic growth Considerations for Future EU Pharmaceutical Strategy	Adrian van den Hoven, Director General, Medicines for Europe
On-Demand Webinar	Novel Excipients Excipients Role in Supporting Innovation and Development Remaining Challenges to the Effective Identification of Novel Excipients Today Barriers & Potential Solutions to Facilitate the Use of Novel Excipients Multifunctional coprocessed excipients for improved tabletting performance The Importance of Excipient Quality: GMPs and Evolving Regulations	Vinit Nigudkar, Global Technical Services & Application Development Staff Scientist– Pharma and Health, Innophos Iain Moore, President, EXCiPACT asbl & Global head of Quality Assurance, Croda International plc Dr Martin Jochen Klatt, Vice President, Sales Pharma Solutions Europe, BASF and EFCG Board member
Live Webinar 16:00 CET	API Trend Outlook 2022 Addressing the Market Outlook for APIs in 2022 Key Driving Factors & Challenges in the Global API market Emerging Product Trends & Market Opportunities Impact of COVID-19 on the Global API Industry Reshoring Realities	Aurelio Arias, Engagement Manager, IQVIA Cathy O’Brien, Managing Director, Enterprise Accounts Europe & ISMEA region, UPS Elisabeth Stampa, CEO of Medichem (Sp) and Board member of EFCG Gian Mario Baccalini, Board member EFCG and representing Aschimfarma Maurizio Schiavazzi, Member of the Managing Committee, CPA Chemical Pharmaceuticals generic Association
	Milano Ecosystem for Life Sciences Milano&Partners is Milano official investment promotion agency, founded by the city and the local Chamber of Commerce. It supports the soft landing of foreign investments in the metropolitan area with a broad offer of free of charge services and promotes Milano's excellence worldwide. Milano Greater Region generates 33% of the Italian registered patents in the EU and supplies 5% of the world's active ingredients. Local Life Sciences production is worth €71 bln with 356,000 people employed. All the main national and EU trade bodies and regulators, including the EFSA (Parma) and EU JRC (Ispra), are based nearby the area. Milano ecosystem for Life Sciences session will explore the macro data and performance of the region and introduce you to a few examples of excellence in the territory.	Piergiorgio Borgogelli, Head of Unit FDIs, Milano&Partners Elena Marangoni, General Manager, IMS Srl Micronizzazioni Pierfrancesco Morosini, Chief Executive Officer, ICROM srl
Learning Lab	Innovate with bi-gels using Emulfree® Duo Patient adherence to skin treatments Bi-gels: formulating new topical drugs Emulfree® Duo, a ready-to-use excipient designed to make bi-gels Case studies	Elise Dauphin-Chanard, Applications Laboratory Manager, Gattefossé
Learning Lab	Effective Solubilization & Bioavailability Enhancement of Poorly Water Soluble APIs Non-ionic solubilizers (VitiPure™ L 20, VitiPure™ O 80, VitiPure™ HCO 40, VitiPure™ CO 35, VitiPure™ P 188) to improve solubility and bioavailability of poorly soluble APIs Well established safety & toxicology via several marketed drugs world-wide Proven effective for all routes of administration and various pharmaceutical dosage forms	Bhushan Thekedar, Technical Application Manager Health Care, Clariant
Learning Lab	Reimagining How You Work with Your Excipient Supplier: Product Quality Beyond Compendial Requirements One of the top priorities of pharmaceuticals companies in bringing new products to market is to prove a drug substance is safe and effective against a certain illness. As you would expect, especially in the beginning stages of development, companies are primarily focused on the API itself and not necessarily the excipients that will go into the final drug product. Instead, compendial requirements and guidelines such as those from ICH exist to ensure excipient quality and safety. Not only it this important from a regulatory perspective, but excipient quality can also impact product performance, even if those excipients meet all compendial requirements. In this session you will learn about: Recent regulatory developments relating to residual impurities in pharmaceutical excipients Challenges in analytical methods to meet increasingly stringent targets How you can work with your excipient supplier to ensure high product quality	Kara Weber, Sr. Technical Service & Development Scientist, Dow
	Driving Excipient Innovation All parties of the pharma supply chain – from manufacturers to patients – want to see the commercialization of innovative products that advance therapeutic treatments. While innovation in the industry remains at the forefront, when it applies to final drug products or to boosting API potency, an often-overlooked element is excipients. Excipients play a crucial role in enabling products to achieve desired performance. New ways of delivering, applying, and manufacturing drug compounds are rising thanks to novel excipients. Patients benefit from improved compliance, alternative routes of delivery, upgraded safety profiles, and advancements that are overcoming unmet medical needs. Grace’s broad range of novel excipients accelerate compliance and enhance bioavailability, solubility, and moisture protection. Discover how we are solving many of today’s challenges in drug delivery and formulation.	Thomas Sobik Pharma Account Executive EMEA W. R. Grace Bob Duffy Pharma Account Executive North America W. R. Grace

26th October 2021

Product Innovation - Manufacturing Equipment, Approaches & Technologies

On-Demand Webinar	Pharma 4.0: Automation & Assembly Solutions for Smart Manufacturing  Current Market Trends Pharma 4.0 and Digital transformation Benefits of Modular Manufacturing in Pharma Automation and Digitization for Device Manufacturing	Yuliya Sayenko, Product Management Device Assembly and Packaging Equipment, Stevanato Group Pushkar Pendse, Principal Consultant, Industry 4.0, TÜV SÜD Digital Service Ewelina Flamm, Associate Director, Merck Stephen Wing, Head of Analytical & Logistical Services, MilliporeSigma Alison Kilduff, Global Facilitator and Account Manager, BioPhorum
On-Demand Webinar	India - Pharma Innovation Landscape Opportunities and Challenges in the Indian Pharma Market Key Innovation Drivers for Growth Forthcoming Challenges and Required Skill-sets for the Indian Pharmaceutical Industry Potential Breakthroughs in Next-Generation Products (non-generics) Outlook for 2022 and Beyond	Dinesh Dua, Executive Director on Board, Nectar Lifesciences Limited Sriram Shrinivasan, Global Generics Leader and India Health & Lifesciences Leader, EY
On-Demand Webinar	Pharma Machinery Trend Outlook A Look at the Current Pharma Machinery Landscape Moving from High to Low Volume Drug Manufacturing for Smaller patient populations Automation, Optimisation and Digital Advances The Use of Robotics in Sterile Fill Finish Single-Use Tech	Keith Dodson, Vice President of Global Business Development, AST
Live Webinar 16:00 CET	Technology Selection for Bioavailability Enhancement Solving Complex Bioavailability Challenges Understanding the 'Molecule for Bioavailability' Technology Selection Explore Advanced Technologies to Overcome Challenges & Increase Speed to Market Validating a Technology Selection Process-BioPhorum Technology Roadmap Vision 2.0	Lisa Caralli, Science and Technology Director, Pharmaceutics ,Catalent Pharma Solutions Guido Kremer-van der Kamp, Senior Consultant, Global BioPharm Center of Excellence, Merck
Learning Lab	Boost your Drug Bioavailability with Labrafac™ MC60, Glycerol Monocaprylocaprate Using Lipid-based formulations to address oral bioavailability issues Labrafac™ MC60, glycerol monocaprylocaprate, Gattefossé new bioehancer Case study: step-by-step development of a lipid-based formulation of dutasteride with Labrafac™ MC60 Gattefossé technical expertise	Elsa Gattefossé, Formulation Scientist, Gattefossé
Learning Lab	Aseptic manufacturing – design of lines for filling and lyophilisation Learn about: Design and realisation of lines for filling and lyophilisation of drug products Development of a lyophilisation cycle for an mRNA vaccine candidate in 2 months Reduction of lyophilisation cycle during optimisation process	Thomas Becker, Quality Director and Qualified Person, Recipharm
Learning Lab	New Technology in Enteric Release: OptiGel® DR Enteric Release Softgels As consumer brands look to provide enhanced benefits or more meaningful differentiation, dose delivery technology and format choice offer innovation opportunities. New OptiGel® DR Enteric Release Softgels enable enteric release benefits without the compromise. Enteric release market Existing challenges to enteric release Benefits of new OptiGel® DR softgels	Dan Peizer, Vice President, Global Marketing & Strategy - Consumer Health, Catalent

27th October 2021

Market Insights & Product Innovation - Biologics, Bioprocessing & Biomanufacturing

On-Demand Webinar

In Partnership with Bioproduction

Addressing viability and commercial challenges of manufacturing Large Biologics:

The Economics of Seed Train Intensification
A Technical End-to-End Project Review to Ensure Commercial Viability of Biologic Products
Developability to Ensure Streamlined Manufacturing
Predictive manufacturability testing prior to development in order to ensure the selection of compatible molecules

Jianlin (Jim) Xu, Principal Scientist, Bristol-Myers Squibb

Benjamin Neunstoecklin, Lead Process Engineer, MSAT Biotech, Bayer, Switzerland

Jonathan Kingsbury, Head of Developability & Pre-Formulation, Sanofi

On-Demand Webinar

China: Opportunities & High Growth Potential for Global and Domestic Pharma

Market dynamics & industry trends
Opportunities in drug development and clinical research
Best practices in supporting global pharma companies to access China
How pharma companies in China can leverage the experience of the global market

Anil Kane, Global Head of Technical & Scientific Affairs, Patheon Inc. part of Thermo Fisher Scientific, Thermo Fisher Scientific

Annie Siu, Director, APAC Content, Informa Pharma Intelligence

Live Webinar 16:00 CET

What is Driving Consolidation in the Pharmaceutical Contract Services Industry?

What’s shaping the future of the outsourcing industry?
Will it remain fragmented or more consolidated?
What is the outcome for the pharmaceutical industry?
To what extent is private equity investment changing the outsourcing services business?
What will the pharmaceutical services industry look like in 5 years?

Dr Fintan Walton, CEO, PharmaVentures

Mark Bamforth, Exec. Chair and CEO, ArrantaBio

Amit Karna, Partner, Keensight Capital

Dr Thomas Dobmeyer, CEO, PharmaLex

Mark Andrews, Managing Director, PharmaVentures

OneBio® – Leveraging Next Gen Technology to Speed the Path to Clinic

Speed to first-in-human studies can be challenging for biologics due to their complex nature. Catalent Biologics’ OneBio integrated solution leverages next generation technology, including GPEx® Lightning cell line development, and integrated program management to shorten the timeline to bring biologic therapies to patients. Learn about Catalent’s streamlined approach and latest investments to support pre-clinical to early-stage programs across drug substance, drug product, analytical and clinical supply logistics

Steven Hager, Director, Science & Technology, Catalent Biologics

28th October 2021

Market Insights & Product Innovation - Packaging & Drug Delivery Solutions

On-Demand Webinar	Paediatric Drug Delivery: Challenges and Solutions Critical development & administration challenges for paediatric medicines New technologies for developing and delivering optimal dosage forms Advantages and Disadvantages of Standard and Novel Strategies for Drug Administration in Paediatrics Emerging Opportunities	Carsten Huettermann, Senior Application Scientist, Pharma Solutions, IFF Pharma Catherine Tuleu, PhD, Professor in Paediatric Pharmaceutics, UCL School of Pharmacy Manel Chikh, Founder & CEO, My BubbleHealth
On-Demand Webinar	Environmental Sustainability in Pharma Historical perspective and importance for healthcare Policy drivers and industry initiatives Commercially successful Green products Areas of unmet need Recommendations for the industry	Aurelio Arias, Engagement Manager, IQVIA
On-Demand Webinar	How to Define Your Own Approach to Sustainability (Repurposed from CPhI North America) Pharmaceutical companies cannot fulfil their core mission to improve public health without concurrently addressing our existential environmental risks and social inequities. The most successful sustainability programs involve collaborations across all parts of the organization – e.g., research, engineering, manufacturing, procurement, human resources, corporate affairs, legal, finance. This session will define your approach to sustainability from two perspectives: your organization’s and your personal contributions to advance the effort.	Tom Polton, Principal, NV Sustainability LCC
Learning Lab	Vinyl-free Blister Solutions, Designed to be Fully Recyclable Investing in better is what drives us. Imagine a vinyl-free blister which is designed to be fully recyclable and compatible on all standard equipment, serving optimal performance in health protection and environmental safety.	Tina Jächel, Product Manager Pharma & Health, Klöckner Pentaplast
Learning Lab	Catalent Orally Inhaled & Nasal Drug Delivery Solutions With over 30 years of experience in supporting the development of inhaled products and full commercial-scale manufacturing capabilities, Catalent offers complete, end-to-end solutions across all common inhalation dose forms including DPIs, MDIs, and unit/bi-dose nasal sprays. From early development and device selection through clinical supply, commercial production, packaging, and final product testing, Catalent provides comprehensive inhalation services to help bring more products and better treatments to market faster. Key learning objectives: Understand the latest trends in orally and nasally inhaled therapeutics Learn about Catalent’s end-to-end inhalation manufacturing and development services Why partner with Catalent for your inhalation products	Carolyn Berg, Vice President, Business Development-Inhalation, Catalent
	BD Services & Solutions - Develop. De-risk. Deliver. This session introduces a comprehensive set of services and solutions designed to mitigate the risks associated with combination product development to help you achieve your goals. These services and solutions help you from development all the way through to launch, including container selection, combination product expertise and testing, regulatory and technical documentation support, analytical testing, world-class lab capabilities, ongoing consultation, and more.	Fabien Dubuc, Global Business Director, Combination Product Solutions and Services, BD

29th October 2021

Market Insights & Product Innovation - FDF, Generics & OTC

On-Demand Webinar	Trends Shaping the Future of Cosmeceuticals Identifying Trends in Cosmeceuticals and Nutraceuticals Growth Drivers for the Personal Care Market, Ingredients & Technologies Consumer Driven Trends in Cosmeceuticals Exploring the Opportunity for Pharma	Ryan Nelson, Executive Editor, HBW Insight, Pharma intelligence, Informa (Moderator) John Bailey, Independent Advisor, EAS Consultant Group Rajiv Khatau, Managing Director, Lodaat Pharma
Live Webinar 16:00 CET	Oral Solid Dose Innovation Forefront Key Formulation Variables & Approaches Formulation Development of Complex Oral Dosage Forms Discuss new innovations & emergence of advanced technologies (e.g., 3D Printing) Main Driver and Areas of Growth for Oral-Dose Outsourcing Patient-Centric Innovation	Vincent Jannin, Head of Applications Lab, Lonza Capsules and Health Ingredients Anna Worsley, Senior Formulation Scientist, FabRx Alex Senior, Director of Market Research, Industry Standard Research
Learning Lab	Accelerating Analytical Method Development using Non-Conventional Detection Techniques To understand the challenging issues involved in analytical development using conventional detectors To have a broader discussion on non-conventional detectors and benefits from it usage To discuss on case studies involved in development of methods using non-conventional detectors	Ramesh Jagadeesan, Asst. Vice President, Recipharm
Learning Lab	HPMC Capsules: The Other New Normal HPMC capsules have gained popularity in the pharmaceutical and dietary supplement markets over the past few years. There are no indications of slowing down. Why the increase from R&D through commercial products? Join in on this session to find out more about HPMC capsules, and how they can be the proper choice for your products. See how to “Make It Better”. Why have HPMC capsules become a more popular delivery system? Consumer acceptance Robustness Formulation HPMC’s involvement in complex products	Justin Kalafat, Head - Scientific Business Development, International, ACG
Learning Lab	New Capabilities in Consumer Health There are new and exciting capabilities available to help drive innovation and growth on your consumer health business. From new delivery technologies to new materials to new formulations, invest 20 minutes to learn how many different ways Catalent's Consumer Health team can help your OTC or VMS business.	Dan Peizer, Vice President, Global Marketing & Strategy - Consumer Health, Catalent
	The Importance of Colours and Why it Matters in the Pharmaceutical Market Colour in Health products: insights and perspectives The Colour Lab Services and how it can help you define your next coloured product Titanium dioxide discussion and Lonza CHI solutions	Julien Lamps, Product Manager, Lonza Capsules & Health Ingredients
	Rapid Response to the European Food Safety Authority (EFSA) Ban on TiO2 as a Food Additive as it Relates to Film Coatings Challenges faced when removing TiO2 from film coatings Aquarius TM TF. A reliable and effective alternative to TiO2 in film coatings Improved process economics with Aquarius Genesis TF high-solids TiO2-free film coating	Christian Mühlenfeld, Head of Life Sciences R&D Europe, Middle East & Africa, Ashland Tim Mcarragher, Regulatory Affairs Professional, Europe, Middle East & Africa, Ashland